1. United States Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Eli Lilly and Company

Eli Lilly and Company

1,417.99
USD
+8.61
(+0.61%)
30.81EPS
37.45P/E
1.03TMarket Cap
Feb 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.84
96.85
Basic EPS, GAAP
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23.07
30.89
Free Cash Flow per Basic Share
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.67
13.09
Dividend per Share
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6.02
6.7
Book Value per Share
15.79
13.84
13.18
12.72
10.54
9.3
2.72
5.9
9.42
11.21
11.98
15.81
29.65
45.19
Tangible Book Value per Share
11.91
9.66
4.97
5.16
2.9
7
-8.03
-5.83
-2.73
-0.66
-1.19
2.51
15.77
13.82
Basic Weighted Avg Shares
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
895
893
Sales/Revenue/Turnover
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
86,462
Operating Margin (%)
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
51.25
Depreciation Expense
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,523
1,527
1,767
1,997
2,174
Net Income, GAAP
4,685
2,391
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
27,580
Effective Tax Rate (%)
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
20.68
Profit Margin (%)
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
31.9
Working Capital
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,981
3,400
896
-1,566
4,364
20,401
18,267
LT Debt
4,200
5,333
7,972
8,368
9,941
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
46,986
Total Equity
17,641
15,388
14,590
14,081
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
40,271
Return on Invested Capital (%)
18.89
8.69
9.11
10.48
-0.3
12.77
22.31
25.29
22.01
24.39
16.25
25.66
36.08
33.42
Return on Capital (%)
22.3
10.85
11.08
12.3
-0.86
14.79
44.21
32.16
24.31
24.69
17.84
26.76
35.3
35.33
Return on Common Equity (%)
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
150.18
76.35
63.63
48.92
84.84
101.36
86.1

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4,000
7,050
2,517
LT Borrowings
39,370
47,858
46,986
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
894
892
891
Market Capitalization
821,814
1,069,292
1,031,190

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
54,835
64,672
65,263
Cash, Cash Equivalents & STI
5,282
8,950
4,885
Accounts Receivable, Net
18,429
20,083
22,089
Inventories
14,529
16,793
18,194
Total Current Liabilities
36,634
47,741
46,996
Payables & Accruals
22,576
27,234
29,963
ST Debt
4,000
7,050
2,517
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
22,974
24,397
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.23
7.42
23.07
2026
8.28
7.96
7.24
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6.02
2026
1.73
1.73
1.73
- -
- -

Company Description

Company Profile APIChatGPT
CEO
David A. Ricks
Full Time Employees
50,000
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Lilly Corporate Center Indianapolis IN United States 46285
IPO Date
Jul 9, 1970
CIK
0000059478
Website
lilly.com
Similar Companies
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Novo Nordisk A/S (NYSE:NVO)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Laurus Labs Ltd. (NSE:LAURUSLABS)
Business
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Company News

Company News APIChatGPT

  • 247wallst.com

    Prediction: The Weight-Loss Drug Boom Could Be Just the Beginning for Lilly

  • prnewswire.com

    Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

  • defenseworld.net

    Eli Lilly and Company $LLY Stock Holdings Lifted by Caldwell Trust Co

  • defenseworld.net

    Eli Lilly and Company $LLY Stock Bought by Compass Financial Management LLC

  • defenseworld.net

    Focused Wealth Management Inc Sells 443 Shares of Eli Lilly and Company $LLY

  • defenseworld.net

    Eli Lilly and Company $LLY Stock: AIA Group Ltd Lowers Stake

  • seekingalpha.com

    Eli Lilly: The True Frontier Of Real-World AI Monetization

  • prnewswire.com

    Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue

  • seekingalpha.com

    Eli Lilly: Higher Volume, Lower Realized Prices

  • zacks.com

    Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

  • zacks.com

    LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold?

  • 247wallst.com

    Eli Lilly Just Delivered Another Monster Quarter. But There's More to This Story Than Weight-Loss Drugs

  • seekingalpha.com

    Eli Lilly: Softer Growth Ahead (Rating Downgrade)

  • 247wallst.com

    Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

  • fool.com

    After Eli Lilly's Explosive Earnings Report, Is It Too Late to Buy the Stock?

  • 247wallst.com

    $10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

  • fool.com

    Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030

  • marketbeat.com

    What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call

  • 247wallst.com

    Eli Lilly's Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs

  • zacks.com

    LLY Q3 Earnings Call Highlights Raised Outlook and Obesity Drug Growth